Research programme: monoclonal antibodies - Aridis Pharmaceuticals

Drug Profile

Research programme: monoclonal antibodies - Aridis Pharmaceuticals

Alternative Names: Anti-infective mAbs - Kenta Biotech/Aridis; AR 201 (anti-RSV mAb) - Aridis; AR 401 (anti-AB mAb) - Aridis; AR-201; AR-401; KBAB 401; KBPA 102; KBPA 103; KBPA 104; KBRV 201; KBSA 201; KBSA 302

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kenta Biotech
  • Developer Aridis Pharmaceuticals; Kenta Biotech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acinetobacter infections; Respiratory syncytial virus infections
  • Discontinued Pseudomonal infections

Most Recent Events

  • 12 Mar 2018 Preclinical development for Acinetobacter infections and Respiratory syncytial virus infections is ongoing in USA (Aridis Pharmaceuticals pipeline, March 2018)
  • 12 Mar 2018 Discontinued - Preclinical for Pseudomonal infections in Switzerland (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acinetobacter-infections in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top